• Selective Cytopheretic Device (SCD): A proprietary medical device that modulates the immune system by selectively targeting and removing activated inflammatory cells in critically ill patients.
• SCD for Acute Kidney Injury (AKI): Development and clinical trials are focused on utilizing the SCD to treat critically ill adult patients with acute kidney injury requiring continuous kidney replacement therapy.
• SCD for Pediatric Acute Kidney Injury (PedAKI): Clinical development is also underway for the SCD to treat children with acute kidney injury who require continuous kidney replacement therapy.

Based on the provided background information, SeaStar Medical Holding (symbol: ICU), operating as LMF Acquisition Opportunities, Inc., does not currently have significant operations or major customers in the traditional sense of selling products or services.

The company's primary stated intention is to "effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses." This indicates it is or was a Special Purpose Acquisition Company (SPAC) or a newly formed entity resulting from such a transaction, and as such, it is not yet generating revenue from a customer base.

Eric Schlorff, Chief Executive Officer

Mr. Schlorff has served as the Chief Executive Officer of SeaStar Medical since 2019, overseeing the company's management, strategy, and operations. Before joining SeaStar Medical in 2016, he spent over two decades at Dow Chemical Company in various financial and leadership capacities, including Global Director of Alternative Investments for the Dow Chemical Pension Plan and Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences.

Michael Messinger, Chief Financial Officer

Mr. Messinger was appointed Chief Financial Officer of SeaStar Medical effective November 14, 2025, bringing over 25 years of experience in the healthcare industry, with more than two decades in financing and accounting for drug discovery and development organizations. He previously served as Chief Financial Officer of ContraFect Corporation, where he guided the company through its Nasdaq IPO in 2014, secured multiple financing rounds (including investments from Pfizer Inc.), and managed a $90 million contract with BARDA. His prior roles include senior financial positions at Lexicon Pharmaceuticals Inc. and Coelacanth Corporation, and he began his career as an auditor at Ernst & Young LLP. Mr. Messinger also serves on the board of directors of Filament Health Corp. and as a strategic consultant to biotechnology companies.

Col. (Ret) Kevin Chung, MD, FCCM, FACP, Chief Medical Officer

Dr. Chung joined SeaStar Medical as Chief Medical Officer effective July 1, 2022. A retired Colonel in the U.S. Army, he is recognized for his expertise in burns, multi-organ support, and extracorporeal therapies. Prior to SeaStar Medical, Dr. Chung held academic and leadership positions, including professor and Chair of the Department of Medicine and professor of Surgery at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences. He also served as Chief of the Department of Medicine at Brooke Army Medical Center and was deployed as Chief of the Intensive Care Unit for the 86th Combat Support Hospital in Baghdad, Iraq, and as Director of the Joint Combat Casualty Research Team in Bagram, Afghanistan.

Sai P. Iyer, Ph.D., Senior Vice President, Medical Affairs & Research

Dr. Iyer possesses expertise in clinical trial development and execution, the launch of first-in-class drugs, medical affairs, and evidence generation.

Tom Mullen, Vice President, Operations & Product Development

Mr. Mullen's background includes leadership in business operations, manufacturing, engineering, product development, and regulatory remediation.

The key risks for SeaStar Medical Holding (symbol: ICU) include its financial instability and going concern status, the inherent risks associated with clinical trials and regulatory approvals for its therapies, and ongoing litigation.

1. Financial Instability and Going Concern Risk: SeaStar Medical Holding has explicitly stated to the SEC in May 2026 that there is "substantial doubt about its ability to continue as a going concern". The company is facing "ongoing profitability challenges and negative operating cash flow". The net loss for Q2 2026 was approximately $3.7 million, and its cash on hand decreased significantly from $12 million at the end of 2025 to $7 million by June 30, 2026, highlighting "financing and cash runway squarely in focus for shareholders". The need for additional capital and the potential for further dilutive financing arrangements are significant concerns.
2. Clinical Trial and Regulatory Approval Risks: The future growth of SeaStar Medical is heavily reliant on the successful outcomes of its clinical trials, particularly the NEUTRALIZE-AKI trial, and subsequent regulatory approvals from the FDA. The commercialization of its adult therapies depends on trial success, the modular PMA pathway, and final FDA decisions, making clinical and regulatory risks central to its investment case. Historically, the company faced a rejection of its HDE application for pediatric SCD by the FDA in May 2023, which led to allegations of "deficient compliance controls and procedures" and overstated regulatory prospects.
3. Litigation Risk: SeaStar Medical Holding is currently subject to a pending securities fraud class action lawsuit. This lawsuit alleges that the company made "materially false and misleading statements" concerning its business and operations, including its compliance controls, the HDE Application, financial controls, and its post-merger business and financial prospects. The outcome of this litigation could have significant financial and reputational impacts on the company.

SeaStar Medical Holding (NASDAQ: ICU) focuses on developing therapies based on its patented Selective Cytopheretic Device (SCD) technology to address hyperinflammation in critically ill patients. The company's main products and pipeline indications target various conditions, with the following addressable market sizes:

• QUELIMMUNE (SCD-PED) for pediatric Acute Kidney Injury (AKI) due to sepsis or a septic condition: This therapy is approved by the U.S. Food and Drug Administration (FDA) for critically ill pediatric patients. SeaStar Medical aims to serve approximately 4,000 patients annually in the U.S.. While an exact dollar figure for this "ultra-rare condition" is not directly stated, the company has indicated that the adult AKI market is 50 times larger than the pediatric market in the U.S.. Based on the adult AKI market size, the estimated addressable market for pediatric AKI due to sepsis is approximately $90 million annually in the U.S.
• SCD therapy for adult Acute Kidney Injury (AKI): This is a significant pipeline indication, with a potential addressable market of $4.5 billion annually in the U.S.. This condition impacts over 200,000 adults in the U.S. annually who require continuous renal replacement therapy (CRRT).
• SCD technology across five initial clinical indications: SeaStar Medical estimates a total addressable market of $25 billion to $33 billion in the U.S. for its proprietary Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. FDA approvals. These indications include Adult Acute Kidney Injury (AKI), Cardiorenal Syndrome with no Left Ventricular Assist Device (LVAD), Adult Acute Respiratory Distress Syndrome (ARDS), Adult Hepatorenal Syndrome, and Cardiorenal Syndrome with LVAD.

1. Expanded Adoption of QUELIMMUNE in the Pediatric Acute Kidney Injury (AKI) Market: SeaStar Medical anticipates continued revenue growth from its first commercial product, QUELIMMUNE (SCD-PED), which treats pediatric AKI due to sepsis. The company has reported significant year-over-year revenue increases and a doubling of its hospital customer base, with a stated goal to further expand its presence in this market.
2. Commercialization of the Selective Cytopheretic Device (SCD) Therapy for Adult Acute Kidney Injury (AKI): A major driver of future revenue is the potential approval and commercialization of the SCD therapy for adult AKI. The company is currently conducting the pivotal NEUTRALIZE-AKI trial, with completion of enrollment anticipated between late 2026 and early 2027. The adult AKI market is estimated to be significantly larger, potentially 50 times the size of the pediatric market, representing a multi-billion-dollar annual opportunity.
3. Expansion into Additional Therapeutic Indications through Breakthrough Device Designations: SeaStar Medical's SCD therapy has received multiple Breakthrough Device Designations from the FDA for various indications beyond pediatric and adult AKI. These include systemic inflammatory response in adult and pediatric cardiac surgery, cardiorenal syndrome, end-stage renal disease (ESRD), hepatorenal syndrome (HRS), and hyperinflammation in adult patients with sepsis. These designations facilitate a speedier pathway to approval and commercial launch, offering significant opportunities for new revenue streams.
4. Increased Hospital Customer Base and Utilization: The company has demonstrated a consistent increase in its hospital customer base for QUELIMMUNE, with a goal to continue this expansion. Furthermore, an uptick in orders from existing customers suggests growing acceptance and utilization of the therapy, which is expected to contribute to revenue growth.

Capital Allocation Decisions of SeaStar Medical Holding (ICU)

SeaStar Medical Holding (NASDAQ: ICU) has primarily focused its capital allocation on financing its operations, including significant research and development efforts, and raising capital through various equity issuances over the last 3-5 years. The company became publicly listed in October 2022 through a business combination with LMF Acquisition Opportunities, Inc., a Special Purpose Acquisition Company (SPAC).

Share Issuance

• In October 2026, SeaStar Medical received approximately $3.3 million in gross proceeds from the immediate exercise of certain outstanding warrants. This transaction also involved the issuance of new unregistered warrants to purchase up to an aggregate of 1,708,004 shares of common stock.
• As of October 5, 2026, the company completed a Rule 506(b) exempt offering, selling $3,301,572 in securities, which included options, warrants, or other rights to acquire securities.
• A 1:10 reverse stock split was executed in January 2026, which reduced the number of outstanding shares while proportionally increasing the stock price. The overall number of shares outstanding has significantly increased, with a reported 393.33% increase in one year, indicating substantial dilution from various financing activities.

Inbound Investments

• SeaStar Medical went public in October 2022 through a business combination with LMF Acquisition Opportunities, Inc., a SPAC. This merger provided the company with access to capital markets, with the transaction contemplating an enterprise value of approximately $85 million for SeaStar Medical.
• As part of the SPAC merger, The Dow Chemical Company Pension Plans, an existing investor, committed to further participate through a Private Investment in Public Equity (PIPE) investment.
• The exercise of warrants in October 2026 brought in approximately $3.3 million in gross proceeds, further contributing to the company's capital.

Capital Expenditures

• In the second quarter of 2026, SeaStar Medical invested $2.5 million in research and development, representing a 143.0% increase from the same period in the prior year. This investment is primarily focused on advancing its product pipeline, particularly the adult Selective Cytopheretic Device (SCD) program.
• The company intends to allocate net proceeds from recent capital raises, such as the October 2026 warrant exercise, towards general corporate purposes, which may include additions to working capital and capital expenditures.